X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7908) 7908
Publication (818) 818
Book Review (57) 57
Book Chapter (17) 17
Dissertation (6) 6
Conference Proceeding (5) 5
Magazine Article (5) 5
Newsletter (5) 5
Streaming Video (3) 3
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7099) 7099
male (4235) 4235
female (4024) 4024
index medicus (3572) 3572
adult (3298) 3298
sputum - microbiology (3254) 3254
middle aged (2937) 2937
sputum (2670) 2670
respiratory system (2129) 2129
aged (1849) 1849
tuberculosis (1531) 1531
adolescent (1424) 1424
infectious diseases (1349) 1349
asthma (1310) 1310
microbiology (1071) 1071
mycobacterium tuberculosis - drug effects (1055) 1055
immunology (1015) 1015
inflammation (1001) 1001
treatment outcome (979) 979
diagnosis (940) 940
mycobacterium tuberculosis - isolation & purification (934) 934
microbial sensitivity tests (863) 863
tuberculosis, pulmonary - drug therapy (849) 849
young adult (825) 825
child (821) 821
research article (809) 809
asthma - drug therapy (775) 775
research (764) 764
antitubercular agents - therapeutic use (761) 761
induced sputum (757) 757
cystic fibrosis (726) 726
pulmonary tuberculosis (703) 703
sputum - cytology (691) 691
care and treatment (690) 690
tuberculosis, pulmonary - microbiology (686) 686
patients (680) 680
medicine (670) 670
airway inflammation (655) 655
risk factors (645) 645
analysis (628) 628
infections (619) 619
anti-bacterial agents - therapeutic use (607) 607
health aspects (596) 596
tuberculosis, pulmonary - diagnosis (584) 584
administration, inhalation (583) 583
time factors (575) 575
drug resistance (560) 560
allergy (553) 553
pharmacology & pharmacy (553) 553
sputum - drug effects (548) 548
double-blind method (535) 535
antibiotics (523) 523
multidisciplinary sciences (518) 518
respiratory tract diseases (513) 513
drug therapy (509) 509
mycobacterium-tuberculosis (500) 500
sputum - metabolism (500) 500
animals (499) 499
aged, 80 and over (495) 495
retrospective studies (487) 487
obstructive pulmonary-disease (483) 483
anti-bacterial agents - pharmacology (481) 481
infection (481) 481
disease (479) 479
prospective studies (470) 470
medicine, general & internal (457) 457
studies (451) 451
children (450) 450
science (449) 449
asthma - physiopathology (441) 441
drug resistance, microbial (436) 436
antitubercular agents - pharmacology (435) 435
sensitivity and specificity (434) 434
chronic obstructive pulmonary disease (433) 433
prevalence (432) 432
epidemiology (419) 419
mortality (416) 416
sputum - chemistry (406) 406
chronic disease (392) 392
mycobacterium tuberculosis (392) 392
mycobacterium tuberculosis - genetics (391) 391
child, preschool (387) 387
drug therapy, combination (387) 387
cystic fibrosis - microbiology (375) 375
lung diseases (371) 371
copd (370) 370
respiratory function tests (368) 368
bacteria (364) 364
asthma - immunology (362) 362
critical care medicine (355) 355
biomarkers (351) 351
tuberculosis, multidrug-resistant - drug therapy (347) 347
hiv (346) 346
medical research (346) 346
therapy (342) 342
eosinophils (336) 336
pulmonary/respiratory (333) 333
cystic fibrosis - complications (328) 328
forced expiratory volume (326) 326
severity of illness index (319) 319
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7375) 7375
Japanese (144) 144
German (133) 133
Russian (125) 125
Chinese (65) 65
French (59) 59
Polish (47) 47
Italian (32) 32
Spanish (22) 22
Romanian (16) 16
Czech (5) 5
Danish (5) 5
Dutch (4) 4
Portuguese (4) 4
Turkish (4) 4
Croatian (3) 3
Korean (2) 2
Swedish (2) 2
Ukrainian (2) 2
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS Pathogens, ISSN 1553-7366, 05/2015, Volume 11, Issue 5, p. e1004917
Pulmonary cavities, the hallmark of tuberculosis (TB), are characterized by high mycobacterial load and perpetuate the spread of M. tuberculosis. The mechanism... 
MYCOBACTERIUM-TUBERCULOSIS | ACTIVATED PROTEIN-KINASE | MICROBIOLOGY | IN-VITRO | VIROLOGY | INTERFERON-GAMMA | INFECTION | EXTRACELLULAR TRAPS | NF-KAPPA-B | LUNG INFLAMMATION | T-CELLS | PARASITOLOGY | INNATE IMMUNITY | AMP-Activated Protein Kinases - metabolism | Tuberculosis, Pulmonary - metabolism | Respiratory Mucosa - drug effects | Humans | Mycobacterium tuberculosis - immunology | NF-kappa B - metabolism | Tuberculosis, Pulmonary - drug therapy | Host-Pathogen Interactions - drug effects | Mycobacterium tuberculosis - drug effects | Respiratory Mucosa - pathology | Proteolysis - drug effects | Protein Processing, Post-Translational - drug effects | Matrix Metalloproteinase 8 - metabolism | Respiratory Mucosa - immunology | Mycobacterium tuberculosis - physiology | Adult | Lung - metabolism | Phosphorylation - drug effects | Neutrophils - metabolism | Extracellular Matrix Proteins - metabolism | Neutrophil Infiltration - drug effects | Neutrophils - pathology | Lung - pathology | Immunity, Innate - drug effects | Neutrophils - enzymology | Cells, Cultured | Enzyme Inhibitors - pharmacology | Neutrophils - immunology | Tuberculosis, Pulmonary - pathology | Matrix Metalloproteinase 8 - chemistry | Tuberculosis, Pulmonary - immunology | Active Transport, Cell Nucleus - drug effects | Lung - drug effects | Respiratory Mucosa - metabolism | Sputum - enzymology | Lung - immunology | Cohort Studies | Proteins | Studies | Pathology | Tuberculosis | Biomedical research | Disease | Biopsy | Infections | Kinases | Metabolism | Experiments
Journal Article
American journal of respiratory and critical care medicine, ISSN 1073-449X, 2014, Volume 190, Issue 2, pp. 175 - 184
Rationale: Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with... 
PH | Cystic fibrosis | Pseudomonas aeruginosa | Ivacaftor | CFTR modulator | LUNG-FUNCTION | ivacaftor | MUCIN SECRETION | ADRENERGIC SWEAT SECRETION | MUCOCILIARY CLEARANCE | INTESTINAL PH | CHILDREN | RESPIRATORY SYSTEM | cystic fibrosis | PSEUDOMONAS-AERUGINOSA | INFLAMMATION | DISEASE | QUESTIONNAIRE | CRITICAL CARE MEDICINE | Sputum - microbiology | Lung - microbiology | Pseudomonas aeruginosa - isolation & purification | Follow-Up Studies | Forced Expiratory Volume - drug effects | Sweat - drug effects | Humans | Microbiota - drug effects | Respiratory System Agents - therapeutic use | Hospitalization - statistics & numerical data | Male | Aminophenols - therapeutic use | Quinolones - pharmacology | Aminophenols - pharmacology | Mucociliary Clearance - drug effects | Pseudomonas Infections - prevention & control | Young Adult | Hydrogen-Ion Concentration - drug effects | Quinolones - therapeutic use | Adult | Female | Lung - metabolism | Child | Biomarkers - metabolism | Respiratory System Agents - pharmacology | Cystic Fibrosis - metabolism | Cystic Fibrosis - microbiology | Pseudomonas Infections - complications | Pseudomonas Infections - diagnosis | Treatment Outcome | Lung - physiopathology | Genetic Markers | Sputum - metabolism | Cystic Fibrosis - genetics | Intestine, Small - drug effects | Lung - drug effects | Adolescent | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Intestine, Small - metabolism | Mutation | Cystic Fibrosis - drug therapy | Sweat - metabolism | Original
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 11/2009, Volume 180, Issue 9, pp. 896 - 902
Rationale: The optimal therapeutic regimen and duration of treatment for Mycobacterium abscessus lung disease is not well established. Objectives: To assess... 
Treatment outcome | Lung diseases | Mycobacterium abscessus | Atypical mycobacteria | lung diseases | DIAGNOSIS | INFECTIONS | NONTUBERCULOUS MYCOBACTERIA | CLARITHROMYCIN RESISTANCE | treatment outcome | CHELONAE | atypical mycobacteria | RAPIDLY GROWING MYCOBACTERIA | IN-VITRO | RESPIRATORY SYSTEM | MULTIDRUG-RESISTANT TUBERCULOSIS | SP-NOV | NODULAR BRONCHIECTASIS | CRITICAL CARE MEDICINE | Sputum - microbiology | Lung - microbiology | Cefoxitin - therapeutic use | Lung Diseases - microbiology | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Lung - diagnostic imaging | Lung Diseases - drug therapy | Anti-Bacterial Agents - therapeutic use | Sputum - drug effects | Liver - drug effects | Mycobacterium Infections, Nontuberculous - microbiology | Adult | Female | Anti-Bacterial Agents - adverse effects | Retrospective Studies | Drug Therapy, Combination | Neutropenia - chemically induced | Chemical and Drug Induced Liver Injury - etiology | Doxycycline - adverse effects | Ciprofloxacin - adverse effects | Nontuberculous Mycobacteria - drug effects | Clarithromycin - adverse effects | Doxycycline - therapeutic use | Ciprofloxacin - therapeutic use | Anti-Infective Agents - therapeutic use | Treatment Outcome | Clarithromycin - therapeutic use | Thrombocytopenia - chemically induced | Nontuberculous Mycobacteria - isolation & purification | Amikacin - adverse effects | Amikacin - therapeutic use | Lung - drug effects | Cefoxitin - adverse effects | Mycobacterium Infections, Nontuberculous - drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2012, Volume 109, Issue 15, pp. 5809 - 5814
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 16, pp. 1508 - 1518
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 09/2013, Volume 188, Issue 6, pp. 703 - 709
Journal Article
American Journal of Respiratory Cell and Molecular Biology, ISSN 1044-1549, 11/2011, Volume 45, Issue 5, pp. 977 - 983
We identified a previously unrecognized component of airborne particulate matter (PM) formed in combustion and thermal processes, namely, environmentally... 
Dendritic cell | Neutrophil | Th17 | EPFR | Asthma | DIESEL EXHAUST PARTICLES | OXIDATIVE STRESS | SPUTUM | BIOCHEMISTRY & MOLECULAR BIOLOGY | AIRWAY INFLAMMATION | INNATE | asthma | neutrophil | CELL BIOLOGY | RESPONSES | T(H)17 CELLS | POLLUTION | RESPIRATORY SYSTEM | ULTRAFINE PARTICLES | dendritic cell | Glutathione - metabolism | Dendritic Cells - immunology | Oxidative Stress - immunology | Male | Free Radicals - adverse effects | Th2 Cells - immunology | Th2 Cells - drug effects | CD4-Positive T-Lymphocytes - immunology | Th17 Cells - drug effects | Particulate Matter - chemistry | Particulate Matter - pharmacology | Asthma - immunology | Dendritic Cells - drug effects | Female | B7-1 Antigen - biosynthesis | Neutrophils - microbiology | B7-2 Antigen - immunology | Macrophages, Alveolar - immunology | Disease Models, Animal | B7-1 Antigen - immunology | Neutrophils - drug effects | Particulate Matter - adverse effects | Cells, Cultured | Mice, Transgenic | Glutathione - immunology | Up-Regulation - drug effects | Cell Differentiation - immunology | Animals | B7-2 Antigen - biosynthesis | Up-Regulation - immunology | Cell Differentiation - drug effects | Macrophages, Alveolar - drug effects | Lung - drug effects | Th17 Cells - immunology | Free Radicals - pharmacology | Mice | Mice, Inbred BALB C | Oxidative Stress - drug effects | CD4-Positive T-Lymphocytes - drug effects | Lung - immunology
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9846, pp. 986 - 993
Journal Article
Journal Article